Table 2.

Comparison of the oligodendrocyte differentiation from hPSCs

Differentiation study	Durati on (days)	Efficien cy (OPC)	markers	Method (Neuralization)	Generation of pre- OPC	Transition from Pre-OPC to OPC	OPC to oligodendrocyte
Nistor et al., 2005	42	>80%	OLIG1 SOX10 A2B5 NG2, PDGFRα GalC RIP O4	EB	FGF EGF RA	EGF
Izrael et al., 2007	>45	>80%	OLIG1/2 SOX10 NKX2.2 PDGFRα O4	EB	EGF RA Noggin	EGF FGF Noggin	Noggin
Hu et al., 2009	112	>80 %	OLIG2 NKX2.2 PDGFRα O4	EB	SHH B27 RA FGF2	PDGF IGFI NT3 T3	PDGF IGFI NT3
Stacpoole et al., 2013	100	80%	OLIG2 NKX2.2 NG2 PDGFRα O4	EB with low oxygen	SAG FGF RA (pMN) SAG FGF (forebrain)	PDGF T3 purmorphamine/SAG RA (pMN) PDGF FGF purmorphamine/SAG T3 (forebrain)	SAG PDGF NT3 IGFI T3 cAMP
Wang et al., 2013	140	70- 90%	OLIG2 SOX10 NKX2.2 MBP PDGFRα O4	EB	RA B27 FGF Purmorphamine	PDGF IGFI T3 NT3 Purmorphamine	PDGF IGFI NT3 B27 BDNF
Douvaras et al., 2014	95	70%	OLIG2 SOX10 NKX2.2 MBP O4	Dual-SMAD inhibition (Monolayer)	RA SAG	PDGF HGF IGFI NT3 Insulin T3 Biotin cAMP	Insulin T3 Biotin cAMP AA
Gorris et al., 2015	>90	80%	OLIG1/2 NKX6.2 NKX2.2 NG2 MBP SOX10	EB	PDGF EGF forskolin	PDGF T3 AA Noggin	T3 AA laminin
Piao et al., 2015	70	90%	OLIG2 NKX2.2 SOX10 O1 MBP O4	Dual-SMAD and WNT inhibition	Purmorphamine AA BDNF FGF8	PDGF IGFI T3 cAMP	BDNF AA T3 cAMP

AA: Ascorbic acid RA: retinoic acid EB: Embryoid body